Stock prices in Chinese education companies listed in Hong Kong have come under pressure after the central government issued a draft proposal that would tighten regulations.
Shares in a number of the companies plunged on Monday, with some closing nearly 40 percent lower, though they began clawing back some of the losses in Tuesday trading.
Novartis, Versant hope to repeat Chinook’s success by arming kidney biotech Borealis with $150M
Roche ramps up lab testing capacity for mpox worldwide following WHO declaration
BioMarin creates new-look R&D and deal teams with Roche’s Sabry, Amgen’s Friberg
FDA rejects Regeneron’s blood cancer bispecific, delaying would-be challenger to J&J and Pfizer
Researchers receive $6.9M grant for tau-targeting drug with potential in Alzheimer’s and beyond
BridgeBio launches another offshoot with $300M and early genetic disease programs
PreciseDx picks up $20.7M to advance AI-based breast cancer risk assessment
Medtech VC investment held steady in Q2 with $3.3B of deal value: PitchBook
Despite cash infusion, Windtree still faces money running out within a year
Pain medicine biotech Latigo taps CRO founder for CMO role